Aurobindo Pharma on Thursday said three manufacturing units in Jadcherla, Telangana, inspected by USFDA in January have been classified as voluntary action indicated (VAI).

VAI means USFDA will not take regulatory action because the objectionable conditions if found are minor and may not qualify for enforcement action.

The three units that were classified as VAI are Unit I and Unit-III, manufacture tablets, capsules and soft gel Capsules and a Derma manufacturing facility. All the three units are located at Jadcherla, Mahabubnagar District, Telangana.

All three units were inspected by USFDA from January 9 to January 18, 2023.

Early this week company’s Unit – IX, an API intermediate facility situated at Gundlamachnoor, Sangareddy district, Telangana, has been classified by USFDA for VAI.

The facility was from November 10-18 last year.

The VAI classification has come as a relief for Aurobindo which is struggling with regulatory issues.

The company shares rose 1.30% to close at Rs 480 on BSE on Thursday, while the BSE Sensex gained 0.07% to end 61,319.51 points.